HELICOBACTER PYLORI

In 1983, Warren and Marshall identified Helicobacter pylori, a new gram-negative bacterial pathogen, in patients suffering from gastritis, and this finding led to studies on the relationship between bacterial infection and chronic gastric disease. The pathogen has been shown to be associated with peptic ulcer, chronic gastritis type B and duodenitis. It has been demonstrated that in patients with gastritis, eradication of the bacteria led to healing of the anatomical lesion.
Diagnostic procedures for the detection of the organism generally involve invasive (gastroscopic) techniques for sample collection.
A valid alternative method, non-invasive, is represented by the test for the determination of the antigens contained in the stool samples. The recent Maastricht 2-2000 Consensus Report recommends the use of the stools antigen test as an aid in the diagnosis of H. pylori infections.

Methods:

Immunoenzymatic method for the qualitative determination of H.pylori antigen in stools samples, using a disposable device applied on the Chorus and Chorus TRIO instruments.The test is based on the ELISA principle (Enzyme linked Immunosorbent Assay). The monoclonal antibodies are bound to the solid phase. Antigen is bound to the solid phase through incubation with the extract of faeces. The disposable devices contain all the reagents to perform the test in the Chorus/Chorus TRIO instruments. The results are expressed in index.

Chorus HELICOBACTER PYLORI Ag

Coated with a monoclonal antibody specific for H.pylori

Code 81063
Quantity 12 tests
METHOD CAPTURE ASSAY
TYPE Qualitative Test
DIAGNOSTIC SENSITIVITY 100% CI95%: 90.6-99.9
DIAGNOSTIC SPECIFITY 100% CI95%: 78.4-99.7
INCUBATION TIME < 90 min
SHELF LIFE 12 months from the date of preparation
STORAGE AND STABILITY 0°/28°C

Download

IFU

SDS

CoA